Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules

Nature Medicine

Volumn 17, Issue 12, 2011, Pages 1685-1691

  Mitsunaga, Makoto ^a   Ogawa, Mikako ^a   Kosaka, Nobuyuki ^a   Rosenblum, Lauren T ^a   Choyke, Peter L ^a   Kobayashi, Hisataka ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; PANITUMUMAB; PANITUMUMAB IRDYE 700DX N HYDROXYSUCCINIMIDE ESTER; PHTHALOCYANINE; TRASTUZUMAB; TRASTUZUMAB IRDYE 700DX N HYDOXYSUCCINIMIDE ESTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL MEMBRANE; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SPECIFICITY; FEMALE; IN VIVO STUDY; IRRADIATION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PHOTOIMMUNOTHERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; SKIN TUMOR; TARGET CELL DESTRUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOTHERAPY; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASMS; NIH 3T3 CELLS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856096764     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2554     Document Type: Article

References (27)

1. Waldmann T.A. Immunotherapy: Past, present and future. Nat. Med. 9, 269-277 (2003). (Pubitemid 36362781)
2. Reichert J.M., Rosensweig C.J., Faden L.B. & Dewitz M.C. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23, 1073-1078 (2005). (Pubitemid 41486385)
3. Goldenberg D.M., Sharkey R.M., Paganelli G., Barbet J. & Chatal J.F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 24, 823-834 (2006). (Pubitemid 46671186)
4. Pastan I., Hassan R., Fitzgerald D.J. & Kreitman R.J. Immunotoxin therapy of cancer. Nat. Rev. Cancer 6, 559-565 (2006). (Pubitemid 43980544)
5. Mew D., Wat C.K., Towers G.H. & Levy J.G. Photoimmunotherapy: Treatment of animal tumors with tumor-specific monoclonal antibody- hematoporphyrin conjugates. J. Immunol. 130, 1473-1477 (1983). (Pubitemid 13159902)
6. Sobolev A.S., Jans D.A. & Rosenkranz A.A. Targeted intracellular delivery of photosensitizers. Prog. Biophys. Mol. Biol. 73, 51-90 (2000). (Pubitemid 30252106)
7. Carcenac M. et al. Internalisation enhances photo-induced cytotoxicity of monoclonal antibody-phthalocyanine conjugates. Br. J. Cancer 85, 1787-1793 (2001). (Pubitemid 34081528)
8. Vrouenraets M.B. et al. Development of meta-tetrahydroxyphenylchlorin- monoclonal antibody conjugates for photoimmunotherapy. Cancer Res. 59, 1505-1513 (1999). (Pubitemid 29160118)
9. Vrouenraets M.B. et al. Targeting of aluminum (III) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: Improved efficacy in photodynamic therapy. Cancer Res. 61, 1970-1975 (2001). (Pubitemid 32692015)
10. Hamblin M.R., Miller J.L. & Hasan T. Effect of charge on the interaction of site-specific photoimmunoconjugates with human ovarian cancer cells. Cancer Res. 56, 5205-5210 (1996). (Pubitemid 26383037)
11. Mew D. et al. Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation. Cancer Res. 45, 4380-4386 (1985). (Pubitemid 16224901)
12. Ogawa M., Regino C.A., Choyke P.L. & Kobayashi H. In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies. Mol. Cancer Ther. 8, 232-239 (2009).
13. Yang X.D. et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59, 1236-1243 (1999).
14. Pooler J.P. & Valenzeno D.P. The role of singlet oxygen in photooxidation of excitable cell membranes. Photochem. Photobiol. 30, 581-584 (1979).
15. Ogawa M. et al. Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. Bioconjug. Chem. 20, 2177-2184 (2009).
16. Dougherty T.J. et al. Photodynamic therapy. J. Natl. Cancer Inst. 90, 889-905 (1998). (Pubitemid 28304157)
17. Wilson B.C. & Patterson M.S. The determination of light fluence distributions in photodynamic therapy. in Photodynamic therapy of neoplastic disease, Vol. 1 (ed. Kessel D.) 129-144 (CRC Press, Boca Raton, Florida, USA, 1990).
18. Detty M.R., Gibson S.L. & Wagner S.J. Current clinical and preclinical photosensitizers for use in photodynamic therapy. J. Med. Chem. 47, 3897-3915 (2004). (Pubitemid 38970949)
19. Weishaupt K.R., Gomer C.J. & Dougherty T.J. Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res. 36, 2326-2329 (1976).
20. Patterson M.S., Madsen S.J. & Wilson B.C. Experimental tests of the feasibility of singlet oxygen luminescence monitoring in vivo during photodynamic therapy. J. Photochem. Photobiol. B 5, 69-84 (1990).
21. Thorpe W.P., Toner M., Ezzell R.M., Tompkins R.G. & Yarmush M.L. Dynamics of photoinduced cell plasma membrane injury. Biophys. J. 68, 2198-2206 (1995).
22. Kosaka N. et al. Semiquantitative assessment of the microdistribution of fluorescence-labeled monoclonal antibody in small peritoneal disseminations of ovarian cancer. Cancer Sci. 101, 820-825 (2010).
23. Kosaka N. et al. Microdistribution of fluorescently-labeled monoclonal antibody in a peritoneal dissemination model of ovarian cancer. Proc. SPIE 7576, 757604 (2010).
24. Mandler R., Kobayashi H., Hinson E.R., Brechbiel M.W. & Waldmann T.A. Herceptin-geldanamycin immunoconjugates: Pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res. 64, 1460-1467 (2004). (Pubitemid 38235617)
25. Nanus D.M. et al. Clinical use of monoclonal antibody HuJ591 therapy: Targeting prostate specific membrane antigen. J. Urol. 170, S84-S88 (2003).
26. van Dongen G.A., Visser G.W. & Vrouenraets M.B. Photosensitizer- antibody conjugates for detection and therapy of cancer. Adv. Drug Deliv. Rev. 56, 31-52 (2004). (Pubitemid 38045423)
27. Zhong W. et al. In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring. Br. J. Cancer 101, 2015-2022 (2009).